TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2675580
Drug: Oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 5 mg twice daily
Study: 1090796
Drug: Electron beam
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electron beam therapy
Study: 1090796
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy and external irradiation
Study: 28758716
Drug: 4% TiF4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% TiF4 gel applied three times (TiF4 3)
Study: 28758716
Drug: 4% TiF4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% TiF4 gel applied twice (TiF4 2)
Study: 28758716
Drug: 4% TiF4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% TiF4 gel applied once (TiF4 1)
Study: 28758716
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C1) - no treatment, 2 days of erosive/abrasive cycling
Study: 28758716
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C2) - no treatment, 4 days of erosive/abrasive cycling
Study: 28758716
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C3) - no treatment, 6 days of erosive/abrasive cycling
Study: 23473987
Drug: Acamprosate (anticraving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (anticraving substance) administered for 3 months
Study: 21438799
Drug: Relapse Prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse Prevention (RP) group therapy over a 2-month period
Study: 21438799
Drug: Labor Rehabilitation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Labor Rehabilitation (LR) standard-of-care treatment
Study: 21438799
Drug: Relapse Prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse Prevention (RP) group therapy
Study: 16453054
Drug: 20-week, twice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-week, twice-weekly exercise program (EX1)
Study: 16453054
Drug: 20-week, twice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-week, twice-weekly exercise program (EX2)
Study: 15112279
Drug: Specialized, nutrition‐focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized, nutrition‐focused patient care (oral nutritional support and home total parenteral nutrition [TPN]) along with COX inhibitor (indomethacin, 50 mg twice daily) and EPO (15‐40,000 units per week)
Study: 11665788
Drug: Phosphodiesterase inhibitors
Normalized name: Phosphodiesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase inhibitors (PDEI)
Study: 9743450
Drug: Hydrophilic matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophilic matrix tablet (ER)
Study: 9743450
Drug: Push‐pull osmotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Push‐pull osmotic pump tablet (XL)
Study: 9743450
Drug: Hydrophilic matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophilic matrix tablet (ER) with food
Study: 9743450
Drug: Push‐pull osmotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Push‐pull osmotic pump tablet (XL) with food
Study: 7974365
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of heparin (LDH)
Study: 7974365
Drug: Heparin-dihydergot (HDHE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-dihydergot (HDHE)
Study: 2564280
Drug: Vecuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium administered to 50% of the patients in each anaesthetic group
Study: 4936366
Drug: Intravenous prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prednisolone (1 Gm.)
Study: 23863876
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg × 2)
Study: 23863876
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m²)
Study: 14506952
Drug: HRT (piperazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (piperazine estrone sulfate 0.625 - 1.25 mg/d +/− medroxyprogesterone acetate 2.5 - 5 mg/d)
Study: 8682134
Drug: Metoprolol (Seloken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (Seloken ZOC 200 mg o.d.)
Study: 31072190
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and Ibuprofen
Study: 22270734
Drug: Cervical interlaminar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical interlaminar epidural injections of local anesthetic (lidocaine 0.5%, 5 mL) - Group I
Study: 22270734
Drug: Cervical interlaminar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical interlaminar epidural injections with 0.5% lidocaine, 4 mL, mixed with 1 mL of nonparticulate betamethasone - Group II
Study: 19798060
Drug: Investigational phosphodiesterase
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational phosphodiesterase type 5 inhibitor
Study: 17621727
Drug: Ginger (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (650 mg, three times per day for 4 days)
Study: 17621727
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (25 mg, three times per day for 4 days)
Study: 7661937
Drug: Oral captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral captopril (6.25 mg initial dose titrated up to 50 mg twice daily)
Study: 7661937
Drug: Oral controlled-release
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral controlled-release mononitrate (30 mg initial dose titrated up to 60 mg once daily)
Study: 7661937
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (8 mmol initial bolus followed by 72 mmol for 24 hours)
Study: 3047333
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with cyclophosphamide, fluorouracil, prednisone (CFP)
Study: 28089141
Drug: rHA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHA vaccine at 7.5ug (no adjuvant)
Study: 28089141
Drug: rHA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHA vaccine at 3.8ug with 2% SE
Study: 28089141
Drug: rHA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHA vaccine at 7.5ug with 2% SE
Study: 28089141
Drug: rHA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHA vaccine at 15ug with 2% SE
Study: 16221219
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg three times a day
Study: 16221219
Drug: Both active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both active treatments (Celecoxib and Indomethacin)
Study: 12148101
Drug: Sodium-profiling hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-profiling hemodialysis with dialysate sodium concentration of 140 mmol/L (TAC(140))
Study: 12148101
Drug: Sodium-profiling hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-profiling hemodialysis with dialysate sodium concentration of 147 mmol/L (TAC(147))
Study: 12148101
Drug: Conventional hemodialysis
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional hemodialysis with dialysate sodium concentration of 138 mmol/L (TAC(138))
Study: 3076790
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose enprofylline (2 mg/kg bolus and 1 mg/kg/hour infusion)
Study: 3076790
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose enprofylline (1 mg/kg bolus and 500 micrograms/kg/hour infusion)
Study: 3076790
Drug: Aminophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (5 mg/kg bolus and 500 micrograms/kg/hour infusion)
Study: 21050476
Drug: Ezetimibe/Simvastatin 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Simvastatin 10/20 mg (EZ/Simva)
Study: 21050476
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg (Rosuva)
Study: 17577218
Drug: Ixabepilone 35
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone 35 mg/m² intravenously every 3 weeks
Study: 17577218
Drug: Mitoxantrone 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 14 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily
Study: 17577218
Drug: Third-line crossover
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-line crossover treatment
Study: 3133709
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg trazodone nocte
Study: 3133709
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg trazodone t.d.s.
Study: 16831143
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg/day for 3 months
Study: 12746164
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (daily iron administration)
Study: 12746164
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment (iron administration 2 days a week)
Study: 8724062
Drug: Ceftibuten (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (9 mg/kg/day in one daily dose)
Study: 8724062
Drug: Amoxicillin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (40 mg/kg/day divided into 3 daily doses)
Study: 31446847
Drug: Transport directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transport directly to a comprehensive stroke center for intravenous thrombolysis and endovascular therapy
Study: 31446847
Drug: Transport to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transport to a primary stroke center for intravenous thrombolysis and subsequent transport to a comprehensive stroke center for endovascular therapy if needed
Study: 31519320
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg once daily for up to 24 months
Study: 24954228
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² and cisplatin 75 mg/m² on day 1 (arm A)
Study: 24954228
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine 80 mg/m² on days 1 and 8 (first cycle 60 mg/m²) and cisplatin 80 mg/m² on day 1 (arm B)
Study: 22642740
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose atenolol plus fixed dose losartan
Study: 11488997
Drug: Cisplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (50 mg/m2, six cycles repeated every 28 days)
Study: 10442510
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg once weekly
Study: 10442510
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg once weekly
Study: 7587033
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g twice daily
Study: 7587033
Drug: Cefotaxime 2
Normalized name: cefotaxime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 2 g twice daily
Study: 20150021
Drug: Testosterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (200 mg every 15 days)
Study: 15569555
Drug: First questionnaire
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First questionnaire administered to first 50 randomly selected patients
Study: 15569555
Drug: Second questionnaire
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second questionnaire administered to second group of randomly selected 50 patients
Study: 11030484
Drug: Moclobemide (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (450 to 600 mg/day)
Study: 1308526
Drug: Daily rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rifampicin for 9 months
Study: 1308526
Drug: Standard WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard WHO multidrug regimen (pulsed doses of rifampicin)
Study: 6146390
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam 0.07 mg/kg
Study: 6146390
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 0.2 mg/kg
Study: 6146390
Drug: Intravenous thiopentone
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous thiopentone 3.0 mg/kg
Study: 6146390
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 2.0 mg/kg
Study: 22217432
Drug: High-frequency (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-frequency (15 Hz) rTMS treatment
Study: 20298557
Drug: Group motivational
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group motivational intervention (32 group sessions, 1 to 12 fortnightly, and 13 to 32 monthly)
Study: 8834097
Drug: d‐chlorpheniramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐chlorpheniramine (4 mg)
Study: 28446846
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise program (walking on treadmill, three times weekly until the end of 37 weeks of gestation) with diet control
Study: 22281165
Drug: 0.5% INCB018424
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% INCB018424 phosphate cream
Study: 22281165
Drug: 1.0% INCB018424
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% INCB018424 phosphate cream
Study: 22281165
Drug: 1.5% INCB018424
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% INCB018424 phosphate cream (twice a day)
Study: 22281165
Drug: Calcipotriene 0.005%
Normalized name: CALCIPOTRIENE 0.005% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene 0.005% cream
Study: 22281165
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate 0.05% cream
Study: 20175820
Drug: Bromotetrandrine (BrTet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromotetrandrine (BrTet) 10 mg/m²
Study: 20175820
Drug: Bromotetrandrine (BrTet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromotetrandrine (BrTet) 20 mg/m²
Study: 20175820
Drug: Bromotetrandrine (BrTet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromotetrandrine (BrTet) 30 mg/m²
Study: 11088064
Drug: Preoperative endocrine
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative endocrine therapy (3 to 4 months duration)
Study: 8803300
Drug: Lisinopril with
Normalized name: LISINOPRIL 20 mg / HYDROCHLOROTHIAZIDE 25 mg ORAL TABLET [Lisinopril with Hydrochlorothiazide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril with or without diuretics
Study: 8803300
Drug: Nifedipine with
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine with or without diuretics
Study: 8803300
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (diuretics with or without vasodilators or selective beta-blockers)
Study: 29807945
Drug: Iodine-containing contrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-containing contrast (0.3 mL)
Study: 26655888
Drug: Kefir-fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kefir-fermented milk (1,600 mg) supplemented with calcium bicarbonate (CaCO3, 1,500 mg)
Study: 26655888
Drug: Calcium bicarbonate
Normalized name: CALCIUM BICARBONATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium bicarbonate (CaCO3, 1,500 mg) alone (control)
Study: 23605599
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser treatment
Study: 22216772
Drug: Interactive voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive voice recognition (IVR) intervention designed to prompt medication refills and improve ICS adherence
Study: 18482632
Drug: Cold-pack therapy
Normalized name: Anbesol Cold Sore Therapy
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-pack therapy (vasoconstriction)
Study: 17135646
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan (2.3 mg/m2/d, days 1 through 5, every 21 days) plus best supportive care (BSC)
Study: 14735174
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan
Study: 11132072
Drug: Propacetamol 20
Normalized name: Propanetriol
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol 20 mg/kg i.v.
Study: 11132072
Drug: Piritramide 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piritramide 0.25 mg/kg i.m.
Study: 11132072
Drug: Tramadol 1
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1 mg/kg i.v.
Study: 11132072
Drug: Diclofenac 1
Normalized name: diclofenac 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1 mg/kg i.v.
Study: 9252957
Drug: DHA oil
Normalized name: Ulkenia DHA oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA oil group (1.68 g/d DHA in triglyceride form)
Study: 9252957
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil group (1.33 g EPA and 0.95 g DHA/d as free fatty acids)
Study: 3526532
Drug: Amoxycillin (62
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (62 mg/kg/day)
Study: 3526532
Drug: Pivampicillin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin (80 mg/kg/day)
Study: 27253658
Drug: Suvorexant (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant (40, 80, and 150 mg)
Study: 24385309
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 300 mg
Study: 24385309
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 800 mg
Study: 24385309
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (all doses)
Study: 21052041
Drug: venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine ER (75 to 225 mg/d)
Study: 16632013
Drug: Valsartan, 80
Normalized name: Valsartan, 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan, 80 mg/d (titrated up to 160 mg/d for blood pressure control)
Study: 10963823
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (0.025 U/kg BW)
Study: 10963823
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (0.05 U/kg BW)
Study: 10963823
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (0.025 U/kg BW)
Study: 10963823
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (0.05 U/kg BW)
Study: 10963823
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (any dose)
Study: 8139394
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (30 g/d)
Study: 29368598
Drug: Standard treatment/control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment/control (CN)
Study: 27310241
Drug: Baseline psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline psychological treatment
Study: 27310241
Drug: Baseline antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline antidepressant medications
Study: 23733443
Drug: HiDHA (tuna
Approvals — FDA: no, EMA: no, PMDA: no
Description: HiDHA (tuna oil) supplementation (8 × 1 g capsules per day for 16 weeks)
Study: 23733443
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (placebo) supplementation (8 × 1 g capsules per day for 16 weeks)
Study: 21414950
Drug: Symptom-triggered self-medication
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-triggered self-medication with chlordiazepoxide
Study: 19108693
Drug: Ad5 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5 vaccine
Study: 19108693
Drug: MRKAd5 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRKAd5 vaccine
Study: 15364161
Drug: Morning dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dose of insulin glargine
Study: 15364161
Drug: Evening dose
Normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dose of insulin glargine
Study: 15364161
Drug: Split dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose of insulin glargine
Study: 9894621
Drug: Captopril (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (37.5 mg/day)
Study: 8672317
Drug: Digital pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital pressure applied on the neurovascular sheath during injection of 2% mepivacaine with adrenaline (20 ml) mixed with contrast agent (20 ml).